Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

Abstract Ixazomib is an oral proteasome inhibitor approved in combination with lenalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM). Approval in the United States, Europe, and additional countries was based on results from the phase III TOURMALINE‐MM1 (C16010...

Full description

Bibliographic Details
Main Authors: Jaydeep K. Srimani, Paul M. Diderichsen, Michael J. Hanley, Karthik Venkatakrishnan, Richard Labotka, Neeraj Gupta
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12815

Internet

https://doi.org/10.1002/psp4.12815

Similar Items